Royalty Report: Drugs, Cancer – Collection: 364268


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 364268

License Grant
Scottish Licensor granted the Licensee an exclusive option to obtain certain exclusive worldwide rights to research, develop and commercialize products containing Licensor’s BETi compounds.

The Licensee exercised the Topical BETi Option, granting Licensee a worldwide, exclusive license that is sublicensable through multiple tiers to exploit certain of Licensor’s BETi compounds identified to be suitable for topical administration in all fields. The Licensee has the sole responsibility for development, regulatory, marketing and commercialization activities to be conducted for the licensed topical products.

License Property
BETi (Bromodomain and Extra-Terminal Domain inhibitors) compounds are new chemical entities (“NCE”), in both topical (the “Topical BETi Option”) and oral (the “Oral BETi Option”) formulations for the treatment of any disease, disorder or condition in humans. It is a inhibitor platform for Immuno-Inflammatory Conditions.

The agreement relates to the discovery and development of proprietary Bromodomain and Extra-Terminal Domain inhibitors (“BET inhibitor” or “BETi”) for the treatment of immunology and oncology conditions.

Field of Use
Field of use is for topical and oral treatments for immuno-inflammatory diseases such as the treatment of immunology and oncology conditions and suitable for topical administration in all fields.

IPSCIO Record ID: 183244

License Grant
Licensor granted an exclusive, worldwide license to develop and commercialize cerdulatinib in topical formulation for all indications, excluding oncology to German Licensee.
License Property
Cerdulatinib, is an orally available dual kinase inhibitor that inhibits spleen tyrosine kinase, or Syk, and Janus kinases, or JAK, enzymes that regulate important signaling pathways.  Cerdulatinib is being developed for hematologic, or blood, cancers and inflammatory disorders.
Field of Use
Licensee intends to develop it for the topical treatment of a range of dermatologic conditions.

This agreement is for the pharmaceutical industry, excluding oncology use.

IPSCIO Record ID: 369281

License Grant
Licensor hereby grants to Licensee and its Affiliates, and Licensee and its Affiliates hereby accept, an exclusive (even as to Licensor), royalty-bearing right and license (with the right to grant sublicenses in accordance with the provisions of Agreement) under the Licensor Technology to research, Develop, have Developed, Manufacture, have Manufactured, use, import, Commercialize and have Commercialized the Compound and Licensed Products in and for the Field and Territory.
License Property
Patent Application titles Novel Heterocyclic Compounds as BRD4 Inhibitors.

The BET inhibitor program is from Jubilant a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment.

There is emerging preclinical data showing BET inhibitors may enhance the activity of immuno-oncology agents, such as anti-PD-1/PD-L1 antibodies, providing multiple opportunities for us to combine this novel mechanism within our portfolio.  Epigenetic targeted agents, especially BET inhibitors, have been an area of great interest of ours for some time and are particularly attractive to us because of their effects on c-Myc driven tumors, like aggressive GCB-subtype DLBCL, an area we have seen early activity with TGR-1202 and our proprietary combination referred to as TG-1303.

Field of Use
The sub-license agreement is to develop and commercialize Jubilant’s novel BET inhibitor program in the field of hematological malignancies.

Field means all prophylactic, palliative, therapeutic or diangnostic uses in humans or animals for the prevention, diagnosis and treatment of hematological malignancies, including, without limitation, all Leukemia’s, Lymphoma’s, Multipe Myeloma and Waldenstrom’s Macroglobulinemia.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.